MRNA technology takes on blood cancer in early trial
NCT ID NCT07349849
First seen Jan 22, 2026 · Last updated May 20, 2026 · Updated 20 times
Summary
This early-phase study tests a new mRNA-based drug that targets a protein called CD19 on cancer cells. It is for adults with B-cell blood cancers (like lymphoma or leukemia) who have not responded to standard treatments. The drug is delivered via lipid nanoparticles, similar to COVID-19 vaccines, and aims to control the disease by helping the body attack cancer cells. The main goals are to find a safe dose and check for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B CELL MALIGNANCIES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Department of Hematology, Xinqiao Hospital
RECRUITINGChongqing, Chongqing Municipality, 400037, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.